Antibiotic, Solosec, receives FDA approval as treatment of trichomoniasis

By NewsDesk @infectiousdiseasenews Today, the U.S. Food and Drug Administration (FDA) approved Lupin Pharmaceuticals supplemental New Drug Application (sNDA) to expand the use of SOLOSEC(R) (secnidazole) to include the treatment of trichomoniasis in adults. Trichomonas vaginalis is the most common non-viral, curable sexually transmitted infection (STI) in the U.S., affecting an estimated three to five million people every [...]

The post Antibiotic, Solosec, receives FDA approval as treatment of trichomoniasis appeared first on Outbreak News Today.